MİDE KANSERİ VE ERKEN TANININ ÖNEMİ
Mide kanseri; dünyada malign tümörler arasında dördüncü sıklıkla görülür, Türkiye’de ise beşinci sıklıkla görülür. Tüm dünyada kansere bağlı ölüm nedenleri arasında ikinci sıklıktadır. Geçmiş yıllarda beş yıllık survey %15 iken günümüzde bu oran %32’dir. Bu duruma erken evrede tanı ve etkin tedavi yöntemleri temel etken olmuştur. Bu makale aromaterapinin yararları, etki mekanizması ve hemşirelik için önemini açıklamak amacıyla planlanmıştır.
GASTRİC CANCER AND THE İMPORTANCE OF EARLY DİAGNOSİS
Gastric carcinoma is the fourth-most common cancer worldwide and the fifth-most common malignancy in Turkey. Gastric cancer remains the second leading cause of cancer-related deaths worldwide. The overall 5-year survival rate is 15% in the past decade however it has risen over %32 in the recent years. The major factors influencing survival are diagnosis at early stage and more effective treatment methods.
___
- Kitagawa Y, Dempsey DT. Stomach In: Schwartz SI.
Principles of Surgery. Seventh ed. New York, 2015;
1035–98.
- Dharmarajan S, Halpin VJ, Hawkins WG. Stomach.
The Washington Manual of Surgery.5th Edition.
Washington, 2008;168-80.
- Zinner MJ, Ashley SW. Maingots Abdominal
Operations. 12th ed. London, 2013:463-89.
- Ergüney S, Yavuz N. Mide Tümörleri. Basic Surgical
Dördüncü Baskı. Ankara, 2010; 1277-92.
- De Martel C, Forman D, Plummer M. Gastric cancer:
epidemiology and risk factors. Gastroenterol Clin North
Am. 2013;42(2):219-40.
- Guggenheim DE, Shah MA. Gastric cancer
epidemiology and risk factors. J Surg Oncol.
2013;107(3):230-6.
- Patru CL, Surlin V, Georgescu I, Patru E. Current
issues in gastric cancer epidemiology. Rev Med Chir
Soc Med Nat Iasi. 2013;117(1):199-204.
- Deng DJ. Progress of gastric cancer etiology: Nnitrosamides
1999s. World J Gastroenterol.
2000;6(4):613-8.
- Du M, Wang W, Jin H, Wang Q, Ge Y,Lu J, et al. The
association analysis of lncRNA HOTAIR genetic
variants and gastric cancer risk in a Chinese
population. Oncotarget. 2015;6(31):31255-62.
- Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al.
PD-L1 and gastric cancer prognosis: A systematic
review and meta-analysis. PLoS One.
2017;12(8):e0182692.
- Hu B, El Hajj N, Sittler S, Lammert N. Gastric cancer:
Classification, histology and application of molecular
pathology. J Gastrointest Oncol. 2012;3(3):251-61.
- Nieminen A, Kokkola A, Ylä-Liedenpohja J, Louhimo J.
Early gastric cancer: clinical characteristics and results
of surgery. Dig Surg. 2009;26(5):378-83.
- Gao LM. The book of Gastric Cancer: Diagnosis and
treatment of gastric cancer. Transl Gastroenterol
Hepatol. 2016;1:54.
- Koç HO, Sarı YS, Bektaş H, Tunalı V, Şahin O,
Özakay K, Ersöz Feyzullah E. Do we adequately
diagnose early gastric cancer in Turkey. Turk J
Gastroenterol. 2011;22 (3): 255-9.
- Chon SH, Berlth F, Plum PS, Herbold T, Alakus H,
Kleinert R, et al. Gastric cancer treatment in the world:
Germany. Transl Gastroenterol Hepatol. 2017; 2:53.
- Şenateş E, İnce Aİ. Erken Mide Kanseri. Güncel
Gastroenteroloji. 2011;15(3):161-66.
- Sydiuk A. Current practice for gastric cancer treatment
in Ukraine. Transl Gastroenterol Hepatol. 2017;2:47.
- Yang K, Hu JK. Gastric cancer treatment: similarity
and difference between China and Korea. Transl
Gastroenterol Hepatol. 2017 ;2:36.
- Kumagai K. Current Status and Future Views of
Gastric Cancer Treatment in Elderly Patients. Gan To
Kagaku Ryoho. 2016;43(9):1058-62.
- Lazăr DC, Tăban S, Cornianu M, Faur A. New
advances in targeted gastric cancer treatment. World J
Gastroenterol. 2016;22(30):6776-99.
- Japanese Gastric Cancer Association. Japanese
gastric cancer treatment guidelines 2014 (ver. 4).
Gastric Cancer. 2017 ;20 (1):1-19.
- Mihmanlı M. Mide Kanseri ve Cerrahi Tedavisi.
İstanbul, 2004;175-204.
- Alimoğlu O, Atak İ, Eren T, Kılıç A. Robot yardımlı
laparoskopik (ROYAL) gastrektomi: Olgu serisi ve
literatürün gözden geçirilmesi Robot assisted
laparoscopic (RAL) gastrectomy: case series and a
review of the literature, Ulusal Cer Derg. 2013;29:
187-91.
- Ghosn M, Tabchi S, Kourie HR, Tehfe M. Metastatic
gastric cancer treatment: Second line and beyond.
World J Gastroenterol. 2016;22(11):3069-77.